Proving the Business Case for the Internet of Things

Prototype wearable could detect cancer in blood

Steve Rogerson
April 4, 2019



Engineers and doctors at the University of Michigan have developed a prototype wearable device that can continuously collect live cancer cells directly from a patient’s blood. Tested in animal models, it could help doctors diagnose and treat cancer more effectively.
 
“Nobody wants to have a biopsy,” said Daniel Hayes, professor of breast cancer research at the University of Michigan and senior author on the paper in Nature Communications. “If we could get enough cancer cells from the blood, we could use them to learn about the tumour biology and direct care for the patients. That’s the excitement of why we’re doing this.”
 
Tumours can release more than 1000 cancer cells into the bloodstream in a single minute. Current methods of capturing cancer cells from blood rely on samples from the patient, usually no more than a tablespoon taken in a single draw. Some blood draws come back with no cancer cells, even in patients with advanced cancer, and a typical sample contains no more than ten cancer cells.
 
Over a couple of hours in the hospital, the device could continuously capture cancer cells directly from the vein, screening much larger volumes of a patient’s blood. In animal tests, the cell-grabbing chip in the wearable device trapped 3.5 times as many cancer cells per millilitre of blood compared with conventional blood draw samples.
 
“It’s the difference between having a security camera that takes a snapshot of a door every five minutes or takes a video,” said Sunitha Nagrath, an associate professor of chemical engineering, who led the development of the device. “If an intruder enters between the snapshots, you wouldn’t know about it.”
 
Research shows that most cancer cells can’t survive in the bloodstream, but those that do are more likely to start a new tumour. Typically, it is these satellite tumours, called metastases, that are deadly, rather than the original tumour. This means, cancer cells captured from blood could provide better information for planning treatments than those from a conventional biopsy.
 
The team tested the device in dogs at the Colorado State University’s Flint Animal Cancer Center in collaboration with Douglas Thamm, a professor of veterinary oncology and director of clinical research there. They injected healthy adult animals with human cancer cells, which are eliminated by the dogs’ immune systems over the course of a few hours with no lasting effects.
 
For the first two hours post-injection, the dogs were given a mild sedative and connected to the device, which screened between one and two per cent of their blood. At the same time, the dogs had blood drawn every 20 minutes, and the cancer cells in these samples were collected by a chip of the same design.
 
The device shrinks a machine that is typically the size of an oven down to something that could be worn on the wrist and connected to a vein in the arm. For help with the design, the engineering team turned to Laura Cooling, a professor of clinical pathology at the university and associate director of the blood bank, where she manages the full-size systems.
 
“The most challenging parts were integrating all of the components into a single device and then ensuring that the blood would not clot, that the cells would not clog up the chip, and that the entire device is completely sterile,” said Tae Hyun Kim, who earned his PhD in electrical engineering in the Nagrath Lab and is now a postdoctoral scholar at the California Institute of Technology.
 
They developed protocols for mixing the blood with heparin, a drug that prevents clotting, and sterilisation methods that killed bacteria without harming the cell-targeting immune markers, or antibodies, on the chip. Kim also packaged some of the smallest medical-grade pumps in a 3D-printed box with the electronics and the cancer-cell-capturing chip.
 
The chip itself is a twist on one of the highest-capture-rate devices from Nagrath’s lab. It uses the nanomaterial graphene oxide to create dense forests of antibody-tipped molecular chains, enabling it to trap more than 80 per cent of the cancer cells in whole blood that flows across it. The chip can also be used to grow the captured cancer cells, producing larger samples for further analysis.
 
In the next steps for the device, the team hopes to increase the blood processing rate. Then, led by Thamm, they will use the optimised system to capture cancer cells from pet dogs that come to the cancer centre as patients. Chips targeting proteins on the surfaces of canine breast cancer cells are under development in the Nagrath lab.
 
Hayes estimates the device could begin human trials in three to five years. It would be used to help optimise treatments for human cancers by enabling doctors to see if the cancer cells are making the molecules that serve as targets for many newer cancer drugs.
 
“This is the epitome of precision medicine, which is so exciting in the field of oncology right now,” said Hayes.